NIH STTR 2026: Deadlines, Funding, Eligibility & SBIR
Quick Answer: NIH STTR is the small-business route for a project that requires a formal nonprofit research-institution partner.
In this guide (11 sections)
- 2026 NIH STTR Program Table
- NIH STTR Versus SBIR Decision Matrix
- NIH STTR Eligibility Checklist
- NIH STTR Funding Amounts and Project Periods
- NIH STTR Deadline and 2026 Workback Plan
- Phase I, Phase II, Fast-Track, or Direct to Phase II
- Clinical-Trial and Institute Fit
- Application Components and Partner Documents
- What NIH Doesn't Tell You in One Place
- NIH STTR Go or No-Go Scorecard
- Sources
Get deadline alerts for these grants
Enter your email for a weekly email of upcoming grant deadlines.
No spam. A weekly email with upcoming grant deadlines.
Full answer: NIH STTR is the small-business route for a project that requires a formal nonprofit research-institution partner. This guide is for small businesses and university spinouts choosing NIH STTR or SBIR. The active parent notice is PA-27-102. It opened August 5, 2026 and listed September 5 as the first standard receipt date (moved to September 8 for the weekend and federal holiday); the next standard receipt date is January 5, 2027, according to PA-27-102's full announcement. NIH weekend and federal-holiday policy moves that 2026 date to Tuesday, September 8, at 5 p.m. applicant-organization local time. STTR requires at least 40% of the research at the small business and at least 30% at one partner institution. According to NIH SEED, the current total-cost guidelines are $335,937 for Phase I and $2,239,578 for Phase II, but PA-27-102 permits higher component limits.
It also supports technology-transfer teams and academic founders. Skip STTR if the small business can't be the applicant, no eligible nonprofit partner will perform at least 30% of the work, or the company can't perform at least 40%.
Start with the exact route: Check the live PA-27-102 NIH STTR record, compare PA-27-100 NIH SBIR, and use the NIH grant hub before drafting.
NIH STTR and SBIR Grants: 2026 Deadlines, Rules, and Funding
Last updated: November 4, 2026
Source review by Grantsights, July 29, 2026: We checked NIH SEED's current opportunity table, the revised PA-27-102 and PA-27-100 full announcements, NIH standard due-date policy, NOT-OD-26-090, current NIH eligibility and application instructions, and SBA workshare policy. We removed expired PA-20-195 guidance, unsupported success rates, old award guidelines, fixed-duration claims, and unverified personal credentials.
Data note: NIH SEED's $335,937 Phase I and $2,239,578 Phase II amounts are total-cost guidelines, not universal caps. PA-27-102 publishes limits by participating component. The exact notice, component table, waiver topic, and program-officer response control the budget.
2026 NIH STTR Program Table
The current parent and follow-on routes were all released May 28, 2026. The table separates the stage and applicant decision before the team starts forms.
| Route | Best fit | Current amount or limit | Timing and status | Next action |
|---|---|---|---|---|
| PA-27-102 NIH STTR R41/R42 | Small business with one required nonprofit research partner | NIH guideline: $335,937 Phase I and $2,239,578 Phase II; component limits can be higher | Opened August 5, 2026; the September 5, 2026 date (adjusted to September 8 under weekend and holiday policy) has passed. The notice stays active through its April 6, 2027 expiration, so the next standard due date is January 5, 2027. | Check the current STTR record |
| PA-27-100 NIH, CDC, and FDA SBIR R43/R44 | Small business that can lead without the formal STTR partner structure | Same NIH guideline, with a separate component table | Opened August 5, 2026; the September 5, 2026 standard date has passed. The notice stays active through its April 6, 2027 expiration, so the next standard due date is January 5, 2027. | Compare the current SBIR record |
| PA-27-101 NIH SBIR Phase IIB R44 | Eligible prior Phase II project needing an added development period and matching funds | Component and notice limits apply; 100% third-party matching funds are required | Opened August 5, 2026; the September 5, 2026 standard date has passed. The notice stays active through its April 6, 2029 expiration, so the next standard due date is January 5, 2027. | Review the Phase IIB record |
| PAR-27-098 Commercialization Readiness Pilot | Eligible Phase II or Phase IIB company with late-stage technical work outside normal research scope | According to NIH SEED, the CRP guideline is $4,191,495 for up to 3 years | Released May 28, 2026; expires April 6, 2029 | Check the CRP record |
The September 8 adjustment is a calendar result, not a new date printed in PA-27-102. The notice lists September 5, NIH says weekend or federal-holiday dates move to the next business day, September 5 is Saturday, and September 7 is Labor Day. Confirm the date shown in the live submission system because the NOFO and later NIH notices remain controlling.
NIH STTR Versus SBIR Decision Matrix
According to NIH SEED, the money always goes to the small business under both programs. The difference is who must participate, where the work sits, and where the PI may be employed.
| Decision test | NIH STTR | NIH SBIR |
|---|---|---|
| Applicant | Eligible U.S. small business | Eligible U.S. small business |
| Nonprofit research partner | Required | Allowed, not required |
| Small-business workshare | At least 40% in Phase I and Phase II | At least two-thirds in Phase I and one-half in Phase II |
| Research-institution workshare | One partner performs at least 30% | No required minimum |
| Remaining work | Remaining 30% can be split or outsourced | Outsourcing stays within the phase limit |
| PI employment | PI may be employed by the small business or partner institution | Primary employment should be with the small business |
| Current parent notice | PA-27-102, R41/R42 | PA-27-100, R43/R44 |
| Venture-capital ownership path | STTR eligibility does not use the SBIR VC-owned-company path | Certain majority VC, hedge-fund, or private-equity ownership structures may qualify |
Grantsights decision rule: start with employment and workshare, not the phase name. If an academic PI cannot move primary employment to the company but can make a formal commitment to it, STTR may preserve the university role. If no single eligible research institution will perform at least 30%, STTR is the wrong route. If the company cannot perform at least 40%, neither a large university subcontract nor a strong scientific idea fixes eligibility.
For example, a university spinout with a faculty PI, licensed assay IP, and required university core facilities may fit STTR when the company can own at least 40% of the work and the university can own at least 30%. A software company with its own technical team and a university adviser doing 10% of the work is usually a cleaner SBIR structure.
Read the broader SBIR versus STTR comparison when the team is also considering NSF, DOD, DOE, or NASA.
NIH STTR Eligibility Checklist
Treat eligibility as a pre-writing gate. The company is not ready until every required item has an owner and supporting document.
- The small business is the applicant. PA-27-102 doesn't fund a university application with a company subcontract.
- The company is organized for profit and has a U.S. place of business. It must meet the current SBA ownership, control, size, and domestic-operation tests at award.
- The company has no more than 500 employees, including affiliates. Affiliate rules can change the size calculation.
- One eligible research institution is the formal STTR partner. The partner can be a U.S. nonprofit college or university, another nonprofit research organization, or an eligible federally funded research and development center.
- The workshare math passes. The company has at least 40% and the single partner has at least 30% in both phases.
- The PI relationship passes. The PI may sit at either party, must have a formal appointment with or commitment to the applicant company, and must commit at least 10% effort under PA-27-102.
- The project fits a participating NIH component. Participation, topic interest, budget limit, clinical-trial acceptance, and Direct-to-Phase-II availability are component-specific.
- The company passes foreign-relationship and disclosure rules. PA-27-102 does not permit foreign organizations or foreign components to apply and does not allow funded foreign subawards under this parent notice.
- Registrations are complete. The company needs SAM.gov and a UEI, the SBA Company Registry, Grants.gov, eRA Commons, and PI ORCID connections.
- The HHS application count passes. NOT-OD-26-090 limits each small business to nine new and resubmission Phase I, Fast-Track, and Direct-to-Phase-II applications or proposals across HHS in a fiscal year.
According to PA-27-102, registration can take 6 weeks or more, and missing registration is not a reason for late submission. A company starting from zero registrations in late July has little margin for the September cycle.
Use the small-business grant hub to compare a nearby route if the applicant, ownership, partner, or R&D test fails.
NIH STTR Funding Amounts and Project Periods
According to NIH SEED, the agency-wide total-cost guideline is:
| Phase | NIH guideline | NIH SEED timeline | PA-27-102 normal statutory period |
|---|---|---|---|
| Phase I, R41 | $335,937 | 6 months to 2 years | Normally no more than 1 year |
| Phase II, R42 | $2,239,578 | 1 to 3 years | Normally no more than 2 years |
| CRP, SB1 | $4,191,495 | Up to 3 years | Use PAR-27-098 |
The two NIH pages express different levels of guidance. NIH SEED gives the general phase ranges, while PA-27-102 states the normal periods and the exact component limits for this parent notice. Build the application from PA-27-102 and the target component's row.
PA-27-102 lists three Phase I budget lanes across participating components:
- the current SBA guideline;
- $400,000; or
- $700,000.
Its Phase II table includes the SBA guideline, $2.5 million, or $3 million, depending on the component. A higher table entry is not an automatic target. The notice says the budget must be reasonable for the work and encourages early contact with the component before a request above the guideline.
Bad fit: do not set the budget from a general blog number, a prior NIH parent notice, or another institute's limit. A $700,000 Phase I request can be within one component's table and outside another's normal limit.
NIH STTR Deadline and 2026 Workback Plan
PA-27-102 opened August 5, 2026 and uses the NIH small-business standard cycle; its next standard receipt date is January 5, 2027, and it expires April 6, 2027, according to PA-27-102's full announcement.
| Listed receipt date | Calendar treatment | Scientific review | Advisory council | Earliest start |
|---|---|---|---|---|
| September 5, 2026 | Adjusted to September 8 because of Saturday and Labor Day | November 2026 | January 2027 | April 2027 |
| January 5, 2027 | Use January 5 unless a later NIH notice changes it | March 2027 | May 2027 | July 2027 |
| April 5, 2027 | Use April 5 unless a later NIH notice changes it | July 2027 | August 2027 | December 2027 |
All applications are due at 5 p.m. applicant-organization local time. PA-27-102 says no late applications will be accepted under this notice.
8-week application workback
- Weeks 8 to 7: confirm company eligibility, partner eligibility, target component, clinical-trial classification, and application count.
- Weeks 7 to 6: finish registrations, assignment strategy, PI appointment or commitment, and STTR model agreement.
- Weeks 6 to 5: lock the specific aims, phase choice, milestones, workshare, IP roles, and go or no-go criteria.
- Weeks 5 to 3: draft the research strategy, facilities, biosketches, data plans, authentication, human-subjects or animal sections, and budget.
- Weeks 3 to 2: finish the commercialization plan, letters, subcontract documents, and component-specific attachments.
- Week 2: run an independent scientific and administrative review against PA-27-102 and Forms I.
- Final week: submit early, clear validation errors, and verify eRA Commons status before the deadline.
If the team cannot complete registrations, partner documents, and the program-officer fit check in time, use the January cycle. A rushed September application does not earn a timing advantage if it fails validation or route fit.
Phase I, Phase II, Fast-Track, or Direct to Phase II
The phase should match the evidence already produced, not the amount the company wants.
Phase I, R41
Use Phase I when the central technical or scientific feasibility question is unresolved. Define a small set of measurable milestones that determine whether Phase II is justified. Preliminary data can support the premise, but the Phase I work still needs a real feasibility question.
Phase II, R42
Use a regular Phase II renewal when the project follows an eligible Phase I award and the team has met its Phase I milestones. PA-27-102 says a Phase II application should be submitted within the first six due dates after the Phase I budget period ends to maintain eligibility.
Fast-Track
NIH Fast-Track submits Phase I and Phase II together for one review. It can reduce the funding gap, but it requires a developed Phase II plan at the first submission. It is a poor fit when the Phase I result could materially change the Phase II design.
Direct to Phase II
NIH Direct to Phase II is for a small business that has already demonstrated the scientific and technical merit and feasibility expected from Phase I without receiving a Phase I SBIR or STTR award for that project. PA-27-102 accepts it for participating NIH components, not as a universal CDC or FDA path.
Grantsights route evidence: based on our review of the current parent notices, the strongest route-changing signal is whether existing data can stand in for a completed Phase I. A prototype alone does not prove that. For example, one company that has analytical validation across intended diagnostic sample types may have a Direct-to-Phase-II case; a company with only a working bench prototype still has a Phase I feasibility question. The common mistake is treating money already spent as proof of feasibility. That fails because NIH asks what technical evidence exists, not what the prototype cost.
Compare the broader SBIR Phase I guide and SBIR award history before choosing a phase.
Clinical-Trial and Institute Fit
PA-27-102 is labeled clinical-trial optional, but that label does not mean every participating component accepts a clinical trial under the notice. The revised announcement identifies components that do not accept clinical trials under this parent route. An application that includes a clinical trial and fits only one of those components is nonresponsive.
Before writing:
- use the NIH clinical-trial definition, not the team's informal label;
- identify the likely institute or center from mission and related awards;
- read that component's funding considerations and budget row;
- check whether the component accepts the proposed clinical trial, Fast-Track, and Direct-to-Phase-II path;
- contact program staff with a short aims summary and the exact route question.
Searching NIH RePORTER can show which components funded related work, but prior awards do not prove current notice eligibility. Use the NIH grants guide for assignment and institute-selection context.
Application Components and Partner Documents
PA-27-102 uses the current SBIR/STTR application instructions and Forms I. The application package is accessed through ASSIST, Grants.gov Workspace, or an institutional system-to-system solution.
| Component | Decision it must support |
|---|---|
| Specific Aims | What technical question will be answered and why it matters to the target component |
| Research Strategy | Why the approach can answer that question, with measurable milestones and alternatives |
| Commercialization Plan | Who needs the product, how adoption works, what evidence lowers market risk, and what comes after NIH funding |
| Budget and justification | Why each cost belongs to the work and how the 40/30 share is calculated |
| Consortium documents | What the partner will do, what it costs, and how the parties coordinate |
| STTR model agreement | How intellectual property rights and follow-on research rights are allocated |
| Facilities and equipment | Where the work occurs and whether each party can perform its assigned share |
| Letters of support | What collaborators, customers, regulators, or end users are actually committing |
| Human-subjects, clinical-trial, or animal sections | Whether the work meets NIH definitions and protections |
The commercialization plan should connect the Phase I or Phase II milestones to a customer, regulatory, reimbursement, manufacturing, or adoption decision. Avoid a market-size paragraph that never changes the research plan.
For writing support, see how to write an SBIR proposal, NIH Specific Aims, and NIH summary statements.
What NIH Doesn't Tell You in One Place
The official pages are authoritative, but they divide the decision across the NIH SEED overview, the funding-opportunity table, the full announcement, component considerations, standard due-date policy, and later notices.
Based on our analysis, five cross-source checks can change the application before writing:
- The printed September 5 date is not the working 2026 deadline. Weekend and Labor Day treatment moves it to September 8.
- The NIH guideline is not every component's cap. PA-27-102 has component rows at the guideline, $400,000, $700,000, $2.5 million, and $3 million.
- Clinical-trial optional is not universal institute acceptance. The project can fit NIH broadly and still be nonresponsive to the only matching component.
- The PI employment fork can decide STTR versus SBIR. The same scientific team may pass STTR and fail SBIR if the faculty PI remains primarily at the university.
- The July 2026 HHS limit changes portfolio planning. A company cannot treat every related concept as another Phase I submission after reaching nine covered new and resubmission applications or proposals in the fiscal year.
This is the Grantsights-only pattern: the route fails most often at the intersection of company role, PI employment, workshare, component participation, and timing. Reading only the award amount misses that intersection. Use the grant database for nearby notices or the free eligibility checker when the team needs a quick fit check before drafting.
NIH STTR Go or No-Go Scorecard
Mark one point for each yes.
- The eligible U.S. small business will be the applicant and awardee.
- One eligible nonprofit research institution will be the formal partner.
- The company can perform at least 40% of the research effort.
- The partner can perform at least 30%.
- The PI has the required company appointment or commitment and at least 10% effort.
- The project fits a participating component's current interests.
- The clinical-trial classification fits that component under PA-27-102.
- The phase matches the evidence already produced.
- The budget fits the component row or has early program-staff support.
- Registrations can be complete before submission.
- The company remains under the HHS fiscal-year application limit.
- The commercialization plan names the next adoption or financing decision.
10 to 12 yes answers: proceed to a program-staff fit check and full workback.
7 to 9 yes answers: repair the missing company, partner, component, or evidence item before drafting.
0 to 6 yes answers: do not apply to PA-27-102 yet. Compare NIH SBIR, a topic-specific small-business notice, an academic NIH mechanism, or a non-NIH route.
Sources
- NIH SEED: current SBIR and STTR funding opportunities
- NIH SEED: understanding SBIR and STTR
- NIH SEED: small-business eligibility criteria
- PA-27-102 revised full announcement
- PA-27-100 revised full announcement
- NIH standard due dates
- NIH submission policies
- NOT-OD-26-090: HHS annual application and proposal limit
- NIH: before you apply
- NIH: prepare your application
- SBA SBIR/STTR policy directives
SBIR agency route chooser
Pick the agency route before writing the SBIR or STTR proposal
SBIR searches split by agency, Phase I timing, STTR partner rules, and proof stage. Choose the route first, then use report data or the official agency path before drafting.
Free SBIR agency fit check
Use this when NIH versus NSF, STTR partner rules, company eligibility, or Phase I timing is still unclear.
No payment on this step.Start free fit checkNext stepCompare SBIR agencies
Use this when the company is choosing between NIH, NSF, DOD, DOE, USDA, NASA, or another SBIR agency.
No payment on this step.Compare agenciesNext stepCheck NIH SBIR/STTR
Use this for health, life-science, clinical, device, diagnostic, digital health, or institute-fit questions.
No payment on this step.Check NIH routeNext stepCheck NSF Seed Fund
Use this when the main question is technical risk, market discovery, or whether a Project Pitch should come first.
No payment on this step.Check NSF routeNext stepSeparate SBIR from STTR
Use this when a university, nonprofit lab, or research partner may change the correct route.
No payment on this step.Check STTR fitNext stepOpen Phase I index
Use this for Phase I amount, baseline eligibility, agency timing, and current program routes.
No payment on this step.Open Phase I indexNIH fit
Health need, institute fit, clinical-trial status, and human-subject rules drive the route.
NSF fit
Technical novelty, market discovery, and Project Pitch readiness drive the route.
STTR fit
A research institution is part of the required project structure, not just an outside helper.
Published by
GrantsightsGrantsights editorial content is reviewed against current NIH SEED, NIH Guide, SBA, Grants.gov, and full-announcement sources. Agency-wide guidelines are kept separate from notice and institute limits.
Source review
Each guide names the primary sources used for its program. Status, deadlines, eligibility, application routes, and award figures are checked against the source that owns that fact before publication. The page identifies its review date and separates current rules from historical planning evidence.
- Primary sources selected from the agency, notice, regulation, or award system that owns each claim
- Status, deadline, eligibility, and award figures rechecked at the page's displayed source-review date
Editorial accountability
Erik Jia, Founder and Editorial LeadAccountable for source standards, corrections, product claims, and data-source transparency.
Source trust
How this guide is reviewed
Each guide is checked against the official notice, agency pages, and federal award records, and it's dated when those facts change.
Frequently Asked Questions
What is the next NIH STTR deadline in 2026?
PA-27-102 lists September 5, 2026 as its first standard receipt date. That date is a Saturday, and NIH policy moves weekend and federal-holiday dates to the next business day. Because September 7 is Labor Day, the adjusted date is September 8, 2026 at 5 p.m. applicant-organization local time. Confirm the displayed date in ASSIST or Grants.gov before submission.
How much can an NIH STTR award provide?
NIH SEED lists total-cost guidelines of $335,937 for Phase I and $2,239,578 for Phase II. PA-27-102 uses those SBA guidelines for some participating components, while others list Phase I limits of $400,000 or $700,000 and Phase II limits of $2.5 million or $3 million. Ask the target NIH component before requesting more than the guideline.
What is the NIH STTR workshare rule?
For both Phase I and Phase II, the small business must perform at least 40% of the research or analytical effort and one partnering nonprofit research institution must perform at least 30%. PA-27-102 measures the shares from direct costs, indirect costs, and fee attributable to each party unless another basis is described and justified.
Can a university professor be the principal investigator on an NIH STTR?
Yes. Under PA-27-102, the principal investigator may be employed by the small business or the single partnering nonprofit research institution. The PI still needs a formal appointment with or commitment to the applicant small business and must commit at least 10% effort to the project.
What is the difference between NIH SBIR and NIH STTR?
STTR requires a formal nonprofit research-institution partner, at least 40% of the work at the small business, and at least 30% at that partner. SBIR does not require that formal partner, permits up to 33% outsourcing in Phase I and 50% in Phase II, and expects the PI's primary employment to be with the small business. The award is made to the small business in both programs.
Last updated: November 4, 2026. This page is reviewed regularly and updated when eligibility requirements, deadlines, or funding amounts change.
Get deadline alerts for grants like these
Enter your email for a weekly email of upcoming grant deadlines. When this guide has a current verified report, the confirmation email links to its free sample. Available reports are $49 each.
No spam. A weekly email with upcoming grant deadlines.
Related Guides
Complete Guide
NIH Grants 2026: Find the Right Mechanism and Apply
Find current NIH grants, compare R01, R21, R03, K, F, T, and small-business routes, check 2026 deadlines, and understand NIH peer review.
NIH R03 Small Grant 2026: Budget, Fit, and Current Parent Route
The NIH R03 funds up to $50,000 in direct costs per year for up to 2 years. No preliminary data required, a 6-page Research Strategy, PA-25-302 route.
How to Read Your NIH Summary Statement (2026 Guide)
Your NIH summary statement has 3 reviewers' critiques and, if discussed, a 10-90 impact score. Decode the wording and decide: resubmit, revise or switch.
NIH Paylines in FY2026: NIA, NIAID, and Score Cutoffs
NIAID stopped using a score cutoff in FY2026, and NIA publishes no general R01 payline. What a percentile still means and when to ask a program officer.
NIH Biosketch 2026: Format, Sections, and What Reviewers Actually Read
NIH biosketch 2026: the SciENcv Common Form and NIH Supplement, the 3,500-character personal statement, 5 contributions, and what reviewers read first.
NIH R01 Success Rates & Award Data: FY2024 and FY2025
NIH R01 success rates fell to 13% in FY2025, down from 18.7% in FY2024. See the breakdown by institute, career stage, and more.